RESUMEN
PURPOSE: Mucopolysaccharidosis IIIA (MPS IIIA) is an inherited lysosomal storage disorder caused by mutations in the N-sulfoglucosamine sulfohydrolase gene that result in deficient enzymatic degradation of heparan sulfate (HS), resulting in progressive neurodegeneration in early childhood and premature death. A chemically modified variant of recombinant human sulfamidase, SOBI003, has shown to cross the blood-brain barrier (BBB) in mice and achieve pharmacologically relevant levels in cerebrospinal fluid (CSF). We report on a phase 1/2, open-label, first-in-human (FIH) study (NCT03423186) and its extension study (NCT03811028) to evaluate the long-term safety, tolerability, pharmacokinetics/pharmacodynamics (PK/PD) and clinical efficacy of SOBI003 in patients with MPS IIIA for up to 104 weeks. METHODS: Six patients aged 1-6 years with confirmed MPS IIIA with developmental age ≥ 12 months received weekly intravenous injections of SOBI003 at 3 mg/kg (Cohort 1, n = 3) or 10 mg/kg (Cohort 2, n = 3). During the extension study, the individual dose of SOBI003 could be adjusted up to 20 mg/kg at the discretion of the investigator. RESULTS: SOBI003 was generally well tolerated. Serum concentrations of SOBI003 increased in proportion to dose, and presence in CSF confirmed that SOBI003 crosses the BBB. Anti-drug antibodies (ADA) were detected in serum and CSF in all patients, with subsequent reductions in serum SOBI003 exposure at high ADA titers. SOBI003 exerted a clear PD effect: a mean reduction in HS levels in CSF of 79% was recorded at the last assessment, together with reductions in HS levels in serum and urine. Neurocognitive development age-equivalent scores showed a stabilization of cognition for all patients, whereas no clear overall clinical effect was observed on adaptive behavior, sleep pattern or quality of life. CONCLUSION: SOBI003 was well tolerated when administered as weekly intravenous infusions at doses of up to 20 mg/kg for up to 104 weeks. ADA development was common and likely affected both PK and PD parameters. SOBI003 crossed the BBB and showed pharmacological activity on HS in CSF.
Asunto(s)
Mucopolisacaridosis III , Anticuerpos , Encéfalo/metabolismo , Niño , Preescolar , Heparitina Sulfato/metabolismo , Humanos , Hidrolasas , Lactante , Mucopolisacaridosis III/tratamiento farmacológico , Mucopolisacaridosis III/genética , Calidad de VidaRESUMEN
Simple and direct determination of sulfate ion concentrations has many important applications, such as analysis of sulfohydrolase activities in biological fluids. Unfortunately, a reported barium-rhodizonate spectrophotometric method with many advantages faces a solubility challenge. To overcome this problem, solvation of rhodizonate complexes in its metathesis reaction was systematically investigated by 46 solvents/compounds using curvilinear regression methods to fit sulfate calibration intervals for signal linearity and color stability. The results revealed solvent structure-activity relationships to the color formation and provided optimal solvent formulae that enable this colorimetry in the stoichiometric way. The limit of water content in the colorimetric matrix increased from 20 to 45% and color formed for reading was stable for 45-135 min. The rhodizonate reagents were stable at -70 °C for >6 months. This established the robustness of the assay, which can now measure the sulfate ion concentration at 0.18 nmol, in comparison to 1 nmol of the early reports. The method provides a simple and direct analysis of sulfate ion, suitable for kinetics studies of sulfohydrolase activity in biological fluids.
Asunto(s)
Bario/química , Líquidos Corporales/química , Ciclohexanonas/química , Sulfatos/análisis , Líquidos Corporales/metabolismo , Colorimetría , Humanos , Hidrolasas/metabolismo , Cinética , Proteínas Recombinantes/metabolismoRESUMEN
Aminopeptidases, which catalyze the cleavage of amino acids from the amino terminus of proteins, are widely distributed in the natural world and play a crucial role in cellular processes and functions, including metabolism, signaling, angiogenesis, and immunology. They are also involved in the homeostasis of amino acids and proteins that are required for cellular proliferation. Tumor cells are highly dependent on the exogenous supply of amino acids for their survival, and overexpression of aminopeptidase facilitates rapid tumor cell proliferation. In addition, clinical studies have demonstrated that patients with cancers with high aminopeptidase expression often have poorer outcomes. Emerging evidence supports the rationale of inhibiting aminopeptidase activity as a targeted approach for novel treatment options, as limiting the availability of amino acids can be selectively lethal to tumor cells. While there are agents that directly target aminopeptidases that demonstrate potential as cancer therapies, such as bestatin and tosedostat, more selective and more targeted therapeutic approaches are needed. This article specifically looks at the biological role of aminopeptidases in both normal and cancer processes, and their potential as a biological target for future therapeutic strategies. When examining previous publications, most do not cover aminopeptidases and their role in cancer processes. Aminopeptidases play a vital role in cell processes and functions; however, their overexpression may lead to a rapid proliferation of tumor cells. Emerging evidence supports the rationale of leveraging aminopeptidase activity as a targeted approach for new oncological treatments. This article specifically looks at the biological role of aminopeptidases in both normal and cancer processes, and their potential as a biological target for future therapeutic strategies.
Asunto(s)
Aminopeptidasas , Neoplasias , Humanos , Aminopeptidasas/química , Aminopeptidasas/metabolismo , Aminoácidos/metabolismo , Aminoácidos/farmacología , Neoplasias/tratamiento farmacológico , Leucina/farmacología , Transducción de Señal , BiologíaRESUMEN
Aim: Accumulation of heparan sulfate (HS) is associated with the neurodegenerative disorder Mucopolysaccharidosis type IIIA (MPS IIIA). Here, we compare HS levels in brain and cerebrospinal fluid (CSF) of MPS IIIA mice after treatment with a chemically modified sulfamidase (CM-rhSulfamidase). Materials & methods: Two LC-MS/MS methods were adapted from literature methodology, one to measure HS metabolites (HSmet), the other to measure digests of HS after heparinase treatment (HSdig). Results: The HSmet and HSdig methods showed similar relative reduction of HS in brain after CM-rhSulfamidase administration to MPS IIIA mice and the reduction was reflected also in CSF. Conclusion: The results of the two methods correlated and therefore the HSdig method can be used in clinical studies to determine HS levels in CSF from patients with MPS IIIA.
Asunto(s)
Encéfalo/metabolismo , Cromatografía Liquida/métodos , Pruebas de Química Clínica/métodos , Heparitina Sulfato/líquido cefalorraquídeo , Mucopolisacaridosis III/líquido cefalorraquídeo , Espectrometría de Masas en Tándem/métodos , Animales , Encéfalo/efectos de los fármacos , Hidrolasas/farmacología , Hidrolasas/uso terapéutico , Ratones , Mucopolisacaridosis III/tratamiento farmacológicoRESUMEN
The truncated [1+9-76] CCL2 analogue, also known as 7ND, has been described in numerous reports as an anti-inflammatory and anti-fibrotic agent in a wide spectrum of animal models, e.g. models of cardiovascular disease, graft versus host disease and bleomycin-induced pulmonary fibrosis. 7ND has been reported to function as a competitive inhibitor of CCL2 signaling via CCR2 in human in vitro systems. In contrast, the mechanistic basis of 7ND action in animal models has not been previously reported. Here we have studied how 7ND interacts with CCL2 and CCR2 of murine origin. Surprisingly, 7ND was shown to be a weak inhibitor of murine CCL2/CCR2 signaling and displaced murine CCL2 (JE) from the receptor with a K(i)>1 µM. Using surface plasmon resonance, we found that 7ND binds murine CCL2 with a K(d) of 670 nM, which may indicate that 7ND inhibits murine CCL2/CCR2 signaling by a dominant negative mechanism rather than by competitive binding to the CCR2 receptor. In addition we observed that sub-nanomolar levels of 7ND mediate anti-fibrotic effects in CCR2 negative fibroblasts cultured from fibrotic lung of bleomycin-induced mice. Basal levels of extracellular matrix proteins were reduced (collagen type 1 and fibronectin) as well as expression levels of α-smooth muscle actin and CCL2. Our conclusion from these data is that the previously reported effects of 7ND in murine disease models most probably are mediated via mechanisms independent of CCR2.